Davis Polk & Wardwell and Zhong Lun Law Firm advised Chinese biopharmaceutical company Antengene Corporation on its $335 million IPO in Hong Kong, with Herbert Smith Freehills and Commerce & Finance Law Offices advising the joint sponsors and the underwriters.

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company offering R&D capabilities and oncology therapies.

The listing is the latest by a Chinese biopharmaceutical company in Hong Kong, which has seen a flurry of such IPOs. Recent other issuers include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.

The Herbert Smith Freehills team was led by Matt Emsley and Stanley Xie.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com

Related Articles

Skadden advises on Trial Holding’s $258 mln Japan IPO

by Nimitt Dixit |

U.S law firm Skadden, Arps, Slate, Meagher & Flom has advised Japanese discount-store chain operator Trial Holdings on its $258 million initial public offering on the Tokyo Stock Exchange (TSE), the largest IPO of the year so far.

Cleary, Freshies lead on China shoemaker’s planned $1 bln HK IPO

by Rowena Muñiz |

Cleary Gottlieb Steen & Hamilton and JunHe are advising Chinese footwear and apparel maker Belle Fashion Group on its planned Hong Kong IPO that is set to raise between $500 million and $1 billion. Freshfields Bruckhaus Deringer and Haiwen & Partners are representing the joint sponsors.

INDIA REPORT: Capital Times on D-Street

by Nimitt Dixit |

It’s been a record-setting year for India’s IPO market, and law firms have reaped the benefits, representing issuing companies and lead managers. And the party isn’t expected to end any time soon: Lawyers believe there is a lot more is to come in 2024 despite the upcoming general elections.